Insmed Provides Clinical Update on Phase 2b CEDAR Study
Go back to Insmed Provides Clinical Update on Phase 2b CEDAR Study| INSMED (NASDAQ: INSM) | Delayed: 91.88 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $91.88 | 52 Week High | $19.30 | |||
| Open | $91.88 | 52 Week Low | $9.02 | |||
| Day High | $91.88 | P/E | N/A | |||
| Day Low | $91.88 | EPS | $-1.69 | |||
| Volume | 101 | |||||

